Instituto de Investigación Biomédica de A Coruña (INIBIC)
Research center
Hospital de Terrassa
Barcelona, EspañaPublications in collaboration with researchers from Hospital de Terrassa (19)
2024
-
Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study
The Lancet Diabetes and Endocrinology, Vol. 12, Núm. 9, pp. 643-652
2022
-
A resilient type of familial hypercholesterolaemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohort
European Journal of Preventive Cardiology, Vol. 29, Núm. 5, pp. 795-801
2020
-
Association of a single nucleotide polymorphism combination pattern of the Klotho gene with non-cardiovascular death in patients with chronic kidney disease
Clinical Kidney Journal, Vol. 13, Núm. 6, pp. 1017-1024
-
Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry
Revista Espanola de Cardiologia, Vol. 73, Núm. 10, pp. 828-834
-
Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation
Cancer Epidemiology, Vol. 67
2019
-
Association of candidate gene polymorphisms with chronic kidney disease: Results of a case-control analysis in the NEFRONA cohort
Frontiers in Genetics, Vol. 10, Núm. FEB
-
Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study
Journal of Clinical Lipidology, Vol. 13, Núm. 6, pp. 989-996
2017
-
Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database
Clinical and Translational Oncology, Vol. 19, Núm. 12, pp. 1537-1542
-
Factors influencing pathological ankle-brachial index values along the chronic kidney disease spectrum: The NEFRONA study
Nephrology Dialysis Transplantation, Vol. 32, Núm. 3, pp. 513-520
-
Predicting cardiovascular events in familial hypercholesterolemia: The SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study)
Circulation, Vol. 135, Núm. 22, pp. 2133-2144
2016
-
Access to Endovascular Treatment in Remote Areas: Analysis of the Reperfusion Treatment Registry of Catalonia
Stroke, Vol. 47, Núm. 5, pp. 1381-1384
-
Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: Insights from the SAFEHEART registry (Spanish familial hypercholesterolaemia cohort study)
Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 36, Núm. 9, pp. 2004-2010
2015
-
Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease
Nephrology Dialysis Transplantation, Vol. 30, Núm. 7, pp. 1176-1185
2014
-
Lipoprotein(a) levels in familial hypercholesterolemia: An important predictor of cardiovascular disease independent of the type of LDL receptor mutation
Journal of the American College of Cardiology, Vol. 63, Núm. 19, pp. 1982-1989
2008
-
Cardiovascular disease in familial hypercholesterolaemia: Influence of low-density lipoprotein receptor mutation type and classic risk factors
Atherosclerosis, Vol. 200, Núm. 2, pp. 315-321
-
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903
Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092
2006
-
Impact of end-stage renal disease care in planned dialysis start and type of renal replacement therapy - A Spanish multicentre experience
Nephrology Dialysis Transplantation, Vol. 21, Núm. SUPPL. 2
2002
-
Heterozygous familial hypercholesterolemia in Spain. Description of 819 non related cases
Medicina Clinica, Vol. 118, Núm. 13, pp. 487-492